For the treatment of osteoporosis it increases bone mass & reduce the incidence of fractures, including those of the hip & spine. Treatment to Increase Bone Mass in Men with Osteoporosis
Treatment of osteoporosis in post-menopausal women: 70/2800 tablet once weekly or 10/400 tablet once daily. Treatment to increase bone mass in men with osteoporosis: 70/2800 tablet once weekly or 10/400 tablet once daily. To permit adequate absorption, it must be taken at least 30 minutes before the first food, beverage or medication of the day with plain water only. Other beverages (including mineral water), food & some medications are likely to reduce the absorption of Alendronate. To facilitate delivery to the stomach & thus to reduce the potential for esophageal irritation, tablet should only be swallowed upon rising for the day with a full glass of water. Patients should not lie down for at least 30 minutes after taking Alendronate until after their first food of the day. Patients should not chew or suck on the tablet should not be taken at bed time.
Abnormalities of the esophagus which delay esophageal emptying, such as stricture or achalasia Inability to stand or sit upright for at least 30 minutes Hypersensitivity to any component of this product Hypocalcaemia Hypocalcaemia & other disturbances of mineral metabolism should be corrected before initiation of therapy. Alendronate can cause local irritation of the upper gastro-intestinal mucosa. Caution should be used when Alendronate is given to patients with active upper gastrointestinal problems such as dysphagia, esophageal disease, gastritis, duodenitis or ulcers. Patients should stop taking medicine & consult their physician if they develop esophageal diseases. No dosage adjustment is necessary for the elderly or for patients with mild-to-moderate renal insufficiency (creatinine clearance 35 to 60 ml/min). It is not recommended for patients with more severe renal insufficiency
Usually mild & generally do not require discontinuation of therapy. Side Effects include esophageal reactions, abdominal pain & distension, diarrhoea or constipation, flatulence, musculoskeletal pain, headache, rash, erythema & transient decreases in serum calcium & phosphate.
Alendronate Sodium is pregnancy category C. Overdoses of vitamin-D have shown teratogenic Effects in pregnant animals. It should be used during pregnancy only if the potential benefit justifies the potential risk to the mother & fetus. Colecalciferol & some of its active metabolites pass into breast milk. It is not known whether alendronate is excreted in human milk. Caution should be exercised when It is administered to lactating women.
.png&w=384&q=75)